<DOC>
	<DOCNO>NCT00822029</DOCNO>
	<brief_summary>It double blind randomized study aim estimate efficiency oral bisphosphonates decrease osteoporosis compare evolution densitometric value two group child ( treatment versus placebo ) .</brief_summary>
	<brief_title>Use Oral Bisphosphonates Treatment Osteoporosis Non-walking Children With Cerebral Palsy</brief_title>
	<detailed_description>In non walk child cerebral palsy , osteoporosis responsible bone pain iterative fracture . Classical treatment include physiotherapy , assist verticalisation orthesis correct feed vitamin D calcium supplementation . Yet n't always sufficient n't always possible . Bisphosphonates , use year treatment post-menopausic osteoporosis osteogenesis imperfecta child , turn useful non-walking child cerebral palsy . Studies publish since 1994 indication encourage result . Cyclic intravenous administration bisphosphonates every 3 month show objective increase bone density decrease pain fracture one year treatment . Cyclic intravenous administration nevertheless require use implanted chamber iterative hospitalization . Oral administration allow treat child , already many treatment , simple way . The study concern 40 non-walking child cerebral palsy age 10 year .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>nonwalking child cerebral palsy weight &gt; = 20 kg age 10 18 year old Zscore ( spinal / femoral ) &lt; 2 DS good dental status capable hold seat half seat position 30 minute capable fill study questionary negative blood pregnancy test inclusion pubescent girl Using valid contraception mean ( condom , oral contraception ) pubescent girl whole study duration 6 month end study affiliate social security regimen history spine arthrodesis osteosynthesis gastrooesophageal reflux oesophagal disease factor lead delay slow oesophagal transit ( stenosis achalasy ) severe difficulty swallow renal failure history uveitis hypersensibility alendronate one excipients ( microcristalline cellulose , lactose anhydre , croscarmellose sodium , magnesium stearate ) deficiency calcium vitamine D calcium malabsorption hereditary galactose intolerance , congenital galactosemia , glucose galactose malabsorption syndrome evolutive affection upper gastrointestinal tract dysphagia ( neurological ) , gastritis , duodenitis , gastroduodenal ulcer ( history ulcer previous year ) , evolutive gastrointestinal bleeding history surgery upper gastrointestinal tract ( gastrostomy particular ) history necrosis maxillar bone uncover bone cicatrisation delay dental surgery emancipate minor prior treatment bisphosphonates inclusion another clinical research study</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>